IGHE and cancer: These findings support the notion that IgE antibodies can activate human macrophages to kill tumour cells ex vivo, but also that both M1 and M2 subsets can engage with antibodies of the ε class and target cancer cells by exerting antigen-specific cytotoxic activity.